Scott Tarriff insider trades: Eagle Pharmaceuticals (EGRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Scott reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 2, 2023 | EGRX | ↓ Sell | 21,619 | $13.84 | $299K | Direct | Nov 3, 2023 (1d) |
| Oct 3, 2023 | EGRX | ↓ Sell | 20,245 | $14.82 | $300K | Direct | Oct 4, 2023 (1d) |
| May 16, 2023 | EGRX | ↓ Sell | 15,000 | $19.98 | $300K | Direct | May 18, 2023 (2d) |
| May 15, 2023 | EGRX | ↓ Sell | 45,000 | $20.68 | $931K | Direct | May 15, 2023 (0d) |
| Apr 1, 2019 | EGRX | ↓ Sell | 24,975 | $50.15 | $1.3M | Direct | Apr 3, 2019 (2d) |
| Mar 1, 2019 | EGRX | ↓ Sell | 24,428 | $51.17 | $1.3M | Direct | Mar 4, 2019 (3d) |
| Feb 1, 2019 | EGRX | ↓ Sell | 30,085 | $41.54 | $1.2M | Direct | Feb 4, 2019 (3d) |
| Jan 3, 2019 | EGRX | ↓ Sell | 31,569 | $39.49 | $1.2M | Direct | Jan 4, 2019 (1d) |
| Apr 1, 2016 | EGRX | ↓ Sell | 30,765 | $40.63 | $1.2M | Direct | Apr 5, 2016 (4d) |
| Mar 1, 2016 | EGRX | ↓ Sell | 19,780 | $63.20 | $1.3M | Direct | Mar 3, 2016 (2d) |
| Feb 1, 2016 | EGRX | ↓ Sell | 18,360 | $68.08 | $1.2M | Direct | Feb 2, 2016 (1d) |
| Jan 4, 2016 | EGRX | ↓ Sell | 14,549 | $85.91 | $1.2M | Direct | Jan 5, 2016 (1d) |
| Dec 1, 2015 | EGRX | ↓ Sell | 14,050 | $88.93 | $1.2M | Direct | Dec 2, 2015 (1d) |
| Nov 2, 2015 | EGRX | ↓ Sell | 19,339 | $64.63 | $1.2M | Direct | Nov 3, 2015 (1d) |
| Oct 1, 2015 | EGRX | ↓ Sell | 17,878 | $69.92 | $1.2M | Direct | Oct 5, 2015 (4d) |
| Sep 1, 2015 | EGRX | ↓ Sell | 16,245 | $76.95 | $1.2M | Direct | Sep 3, 2015 (2d) |
| Aug 3, 2015 | EGRX | ↓ Sell | 13,000 | $96.19 | $1.3M | Direct | Aug 4, 2015 (1d) |
| Jul 1, 2015 | EGRX | ↓ Sell | 135,710 | $46.34 | $6.3M | Direct | Jul 2, 2015 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Scott Tarriff's insider trades
Scott Tarriff is an insider at Eagle Pharmaceuticals (EGRX). Since Jul 1, 2015, Scott has reported no open-market purchases and 18 sales worth $24.4M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (27 filings), shares withheld for taxes (10 filings), option exercises (4 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EGRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.